Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casdatifan in Refractory Clear Cell Renal Cell Carcinoma
NCT07748988Phase 1Recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Sep 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of casdatifan in clear cell renal cell carcinoma (ccRCC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Change in expression of predefined HIF2-regulated target genes in metastatic tumor tissue at 1 year. Started Sep 2026; status: recruiting.
02
Drugs
casdatifan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07748988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748988.